NovoCure Limited develops and commercializes Tumor Treating Fields therapy for solid tumors through wearable medical devices including Optune Gio, Optune Lua and Optune Pax. News about NVCR centers on product approvals, reimbursement decisions, launch activity and the use of TTFields in glioblastoma, pancreatic cancer, non-small cell lung cancer and pleural mesothelioma.
Company updates also cover clinical programs such as PANOVA, LUNAR and KEYNOTE studies, quarterly financial results, research and clinical-study spending, and commercialization across the United States, Europe, Japan and other markets where the company has approved products.
Novocure (NASDAQ: NVCR) has announced results from the TIGER study, which investigated the use of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM) in Germany. The study, conducted from August 2017 to November 2019, included 429 patients and is the largest prospective, non-interventional study of TTFields therapy to date. Key findings indicate a median overall survival of 19.6 months and a median progression-free survival of 10.2 months. The therapy was well tolerated with no increase in systemic toxicity. One-year, two-year, three-year, and four-year survival rates were 79.2%, 42.4%, 31.5%, and 27.7%, respectively. These results align with previous phase 3 EF-14 clinical trial outcomes. The data will be presented at the 2024 American Society of Clinical Oncology Annual Meeting.
Novocure (NASDAQ: NVCR) secured a new $400 million multi-tranche non-dilutive debt financing from Pharmakon Advisors, LP. The facility will be available in four tranches, with the first $100 million issued at closing and the rest to follow by 2026. The funds will support working capital needs for the anticipated launch in non-small cell lung cancer and settle Novocure’s convertible notes. The partnership with Pharmakon strengthens Novocure’s cash position and balance sheet, providing financial stability for future growth.
Novocure (NASDAQ: NVCR) reported strong financial results for the first quarter of 2024 with total net revenues of $138.5 million, up 13% year-over-year. The company had 3,845 active patients on therapy as of March 31, 2024. The METIS Phase 3 clinical trial met its primary endpoint and will be presented at ASCO 2024. Novocure also completed a successful Day-100 meeting with the FDA for the LUNAR PMA application.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.